Faruk Mansoor, U. published the artcileDesign and synthesis of potent Gram-negative specific LpxC inhibitors, Application of 1-Biphenyl-4-yl-piperazine, the publication is Bioorganic & Medicinal Chemistry Letters (2011), 21(4), 1155-1161, database is CAplus and MEDLINE.
Antibiotic resistant hospital acquired infections are on the rise, creating an urgent need for novel bactericidal drugs. Enzymes involved in lipopolysaccharide (LPS) biosynthesis are attractive antibacterial targets since LPS is the major structural component of the outer membrane of Gram-neg. bacteria. Lipid A is an essential hydrophobic anchor of LPS and the first committed step in lipid A biosynthesis is catalyzed by a unique zinc dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). LpxC is an attractive Gram-neg. only target that has been chem. validated by potent bactericidal hydroxamate inhibitors that work by coordination of the enzyme’s catalytic zinc ion. An exploratory chem. effort focused on expanding the SAR around hydroxamic acid zinc-binding warheads’ lead to the identification of novel compounds with enzyme potency and antibacterial activity similar to CHIR-090.
Bioorganic & Medicinal Chemistry Letters published new progress about 180698-19-5. 180698-19-5 belongs to piperazines, auxiliary class Piperazine,Benzene, name is 1-Biphenyl-4-yl-piperazine, and the molecular formula is C16H18N2, Application of 1-Biphenyl-4-yl-piperazine.
Referemce:
https://en.wikipedia.org/wiki/Piperazine,
Piperazines – an overview | ScienceDirect Topics